Carcinoid Tumors

Surgical Oncology Clinics of North America

Volumn 15, Issue 3, 2006, Pages 463-478

  Sippel, Rebecca S ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN A; FENFLURAMINE; KI 67 ANTIGEN; OCTREOTIDE; PROTEIN P53; SEROTONIN; SOMATOSTATIN; TACHYKININ; TUMOR MARKER;

ABDOMINAL PAIN; ACUTE APPENDICITIS; APPENDIX CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CARCINOID; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL TRIAL; COLON CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; ENDOSCOPY; HISTOLOGY; HUMAN; INCIDENTAL FINDING; LABORATORY TEST; LUNG CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECTUM CARCINOMA; REVIEW; SMALL INTESTINE CARCINOMA; STEATORRHEA; STOMACH CARCINOGENESIS; STOMACH CARCINOID; SURGICAL TECHNIQUE; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; APPENDICEAL NEOPLASMS; CARCINOID HEART DISEASE; CARCINOID TUMOR; HUMANS; HYDROXYINDOLEACETIC ACID; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; SEROTONIN; STOMACH NEOPLASMS;

EID: 33746373162     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2006.05.002     Document Type: Review

References (79)

1. Oberndorfer S. Karzinoide tumoren des dunndarms. Frankf Zschr Pathol 1 (1907) 426-430
2. Modlin I.M., and Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 79 (1997) 813-829
3. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 4 (2003) 934-959
4. Van Gompel J.J., Sippel R.S., Warner T.F., et al. Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg 28 (2004) 387-392
5. Tomassetti P. Clinical aspects of carcinoid tumours. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S143-S146
6. Williams E., and Sandler M. The classification of carcinoid tumors. Lancet 1 (1963) 238-239
7. Kloppel G., Perren A., and Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014 (2004) 13-27
8. Kulke M.H., and Mayer R.J. Carcinoid tumors. N Engl J Med 340 (1999) 858-868
9. Chughtai T.S., Morin J.E., Sheiner N.M., et al. Bronchial carcinoid-twenty years' experience defines a selective surgical approach. Surgery 122 (1997) 801-808
10. Smolle-Juttner F.M., Popper H., Klemen H., et al. Clinical features and therapy of "typical" and "atypical" bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma). Eur J Cardiothorac Surg 7 (1993) 121-124
11. Marty-Ane C.H., Costes V., Pujol J.L., et al. Carcinoid tumors of the lung: do atypical features require aggressive management?. Ann Thorac Surg 59 (1995) 78-83
12. Rindi G., Bordi C., Rappel S., et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 20 (1996) 168-172
13. Modlin I.M., Gilligan C.J., Lawton G.P., et al. Gastric carcinoids. The Yale Experience. Arch Surg 130 (1995) 250-255
14. Ahlman H. Surgical treatment of carcinoid tumours of the stomach and small intestine. Ital J Gastroenterol Hepatol 31 Suppl 2 (1999) S198-S201
15. Delle F.G., Capurso G., Milione M., et al. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 19 (2005) 659-673
16. Shebani K.O., Souba W.W., Finkelstein D.M., et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229 (1999) 815-821
17. Burke A.P., Thomas R.M., Elsayed A.M., et al. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 79 (1997) 1086-1093
18. Hellman P., Lundstrom T., Ohrvall U., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26 8 (2002) 991-997
19. Roggo A., Wood W.C., and Ottinger L.W. Carcinoid tumors of the appendix. Ann Surg 217 (1993) 385-390
20. Safioleas M.C., Moulakakis K.G., Kontzoglou K., et al. Carcinoid tumors of the appendix. Prognostic factors and evaluation of indications for right hemicolectomy. Hepatogastroenterology 52 61 (2005) 123-127
21. Rosenberg J.M., and Welch J.P. Carcinoid tumors of the colon. A study of 72 patients. Am J Surg 149 (1985) 775-779
22. Ballantyne G.H., Savoca P.E., Flannery J.T., et al. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer 69 (1992) 2400-2405
23. Jetmore A.B., Ray J.E., Gathright Jr. J.B., et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 35 (1992) 717-725
24. Feldman J.M., and O'Dorisio T.M. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81 (1986) 41-48
25. Kema I.P., de Vries E.G., Schellings A.M., et al. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Clin Chem 38 (1992) 534-540
26. Eriksson B., Oberg K., and Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 62 Suppl 1 (2000) 33-38
27. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol 10 Suppl 2 (1999) S3-S8
28. Bashir S., Gibril F., Ojeaburu J.V., et al. Prospective study of the ability of histamine, serotonin or serum chromogranin A levels to identify gastric carcinoids in patients with gastrinomas. Aliment Pharmacol Ther 16 (2002) 1367-1382
29. Ganim R.B., and Norton J.A. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol 9 (2000) 173-179
30. Reubi J.C., Kvols L.K., Waser B., et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50 (1990) 5969-5977
31. Taal B.G., Hoefnagel C.A., Valdes Olmos R.A., et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14 (1996) 1829-1838
32. Taal B.G., Hoefnagel C.A., Valdes Olmos R.A., et al. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In- pentetreotide in carcinoid tumours. Eur J Cancer 32A (1996) 1924-1932
33. Orlefors H., Sundin A., Ahlstrom H., et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 16 (1998) 2534-2541
34. Sippel R., and Chen H. An update on carcinoid tumors. In: Soper N.J. (Ed). Problems in general surgery (2003), Lippincott Williams & Wilkins, Philadelphia 125-133
35. McDermott E.W., Guduric B., and Brennan M.F. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81 (1994) 1007-1009
36. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 89 3 (2005) 151-160
37. Eckhauser F.E., Lloyd R.V., Thompson N.W., et al. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 104 (1988) 1046-1053
38. Hirschowitz B.I., Griffith J., Pellegrin D., et al. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 102 (1992) 1409-1418
39. Richards M.L., Gauger P., Thompson N.W., et al. Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World J Surg 28 7 (2004) 652-658
40. Jordan Jr. P.H., Barroso A., and Sweeney J. Gastric carcinoids in patients with hypergastrinemia. J Am Coll Surg 199 (2004) 552-555
41. Borch K., Ahren B., Ahlman H., et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242 1 (2005) 64-73
42. Lal A., and Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 18 (2006) 9-15
43. Ohrvall U., Eriksson B., Juhlin C., et al. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24 11 (2000) 1402-1408
44. Moertel C.G., Weiland L.H., Nagorney D.M., et al. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 317 (1987) 1699-1701
45. Naunheim K.S., Zeitels J., Kaplan E.L., et al. Rectal carcinoid tumors-treatment and prognosis. Surgery 94 (1983) 670-676
46. Koura A.N., Giacco G.G., Curley S.A., et al. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 79 (1997) 1294-1298
47. Sauven P., Ridge J.A., Quan S.H., et al. Anorectal carcinoid tumors. Is aggressive surgery warranted?. Ann Surg 211 (1990) 67-71
48. Gulec S.A., Mountcastle T.S., Frey D., et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg 68 (2002) 667-671
49. Wangberg B., Westberg G., Tylen U., et al. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20 (1996) 892-899 discussion 899
50. Boudreaux J.P., Putty B., Frey D.J., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 241 6 (2005) 839-845 discussion 845-6
51. Elias D., Sideris L., Liberale G., et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137 4 (2005) 411-416
52. Robiolio P.A., Rigolin V.H., Wilson J.S., et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92 (1995) 790-795
53. Jick H., Vasilakis C., Weinrauch L.A., et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339 (1998) 719-724
54. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337 (1997) 581-588
55. Musunuru S., Carpenter J.E., Sippel R.S., et al. A mouse model of carcinoid syndrome and heart disease. J Surg Res 126 (2005) 102-105
56. Connolly H.M., Nishimura R.A., Smith H.C., et al. Outcome of cardiac surgery for carcinoid heart disease. J Am Coll Cardiol 25 (1995) 410-416
57. Robiolio P.A., Rigolin V.H., Harrison J.K., et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol 75 (1995) 485-488
58. Chen H., Hardacre J.M., Uzar A., et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg 187 (1998) 88-92
59. Fehmann H.C., Wulbrand U., and Arnold R. Treatment of endocrine gastroenteropancreatic tumors with somatostatin analogues. Recent Results Cancer Res 153 (2000) 15-22
60. Kvols L.K. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin N Am 18 (1989) 557-568
61. O'Toole D., Ducreux M., Bommelaer G., et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 (2000) 770-776
62. Rohaizak M., and Farndon J.R. Use of octreotide and lanreotide in the treatment of symptomatic non- resectable carcinoid tumours. ANZ J Surg 72 (2002) 635-638
63. Nikou G.C., Lygidakis N.J., Toubanakis C., et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 52 63 (2005) 731-741
64. Ruszniewski P., Ducreux M., Chayvialle J.A., et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39 (1996) 279-283
65. Rubin J., Ajani J., Schirmer W., et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17 (1999) 600-606
66. Leong W.L., and Pasieka J.L. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 79 (2002) 180-187
67. Arnold R., Trautmann M.E., Creutzfeldt W., et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 3 (1996) 430-438
68. Aparicio T., Ducreux M., Baudin E., et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 37 8 (2001) 1014-1019
69. Welin S.V., Janson E.T., Sundin A., et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151 1 (2004) 107-112
70. Kvols L.K., Martin J.K., Marsh H.M., et al. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313 (1985) 1229-1230
71. Warner R.R., Mani S., Profeta J., et al. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 61 (1994) 349-355
72. Kinney M.A., Warner M.E., Nagorney D.M., et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 87 3 (2001) 447-452
73. Van Gompel J.J., and Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 136 (2004) 1297-1302
74. Kunnimalaiyaan M., Yan S., Wong F., et al. Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery 138 (2005) 1137-1142
75. Kunnimalaiyaan M., Traeger K., and Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 289 (2005) G636-G642
76. Nakakura E.K., Sriuranpong V.R., Kunnimalaiyaan M., et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90 (2005) 4350-4356
77. Sippel R.S., Carpenter J.E., Kunnimalaiyaan M., et al. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 285 (2003) G245-G254
78. Van Gompel J.J., Kunnimalaiyaan M., et al. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 4 (2005) 910-917
79. Kunnimalaiyaan M., and Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors?. Anticancer Drugs 17 (2006) 139-142